|
|||
DRUGS & SUPPLEMENTS
|
How long you have been taking the medicine? |
Olmetor is an antihypertensive agent, angiotensin II receptor blocker. This medication has a high selectivity to angiotensin II receptor type 1 which are implemented with the participation of the main effects of angiotensin II. By blocking these receptors Olmetor prevents and eliminates the vasoconstrictor action of angiotensin II, causes a secondary increase in plasma renin activity due to elimination of negative feedback for renin release and a direct reduction in aldosterone secretion.
When hypertension Olmetor causes dose-dependent, prolonged reduction of blood pressure.
There are no details about the development of arterial hypotension after the first dose of Olmetor, tachyphylaxis during prolonged treatment and withdrawal.
When taking first time Olmetor provides an effective and mild reduction of blood pressure within 24 hours. Maximum antihypertensive effect is achieved after 8 weeks of the therapy, although a significant effect of blood pressure lowering marked only in 2 weeks of the treatment.
Olmetor is a pro-drug. It quickly turns into a pharmacologically active metabolite of olmesartan under the influence of esterases in the intestinal mucosa and blood of portal vein during absorption from the gastrointestinal tract. In blood plasma or secretions nondecomposed Olmetor or unmodified side chain medoxomil group was not been determined. Cmax of olmesartan in plasma levels reached an average of approximately 2 hours after ingestion and increases almost linearly with increasing dose to 80 mg. Simultaneous ingestion does not affect the bioavailability of olmesartan. Olmesartan binding to plasma proteins is 99.7% but the potential for clinically significant shift values of binding to proteins in the interaction of olmesartan with other drugs that have a high degree of protein binding is low (this is confirmed by the fact that there is no clinically significant interaction between warfarin and olmesartan). Olmesartan is excreted in the urine (approximately 40%) and bile (approximately 60%), T1/2 is 10-15 hours. Cumulation of olmesartan is not marked.
Essential arterial hypertension.
Olmetor is administered orally on a daily basis. The initial dose is 10 mg / day. When inefficiency the dose increases up to the optimum 20 mg / day. If necessary the dose may be increased to the maximum 40 mg / day.
For elderly patients dosage adjustment is not required. If necessary increasing the daily dose to a maximum of 40 mg / day improvement should be under careful control of blood pressure. For patients with impaired mild or moderate renal function the maximum daily dose is 20 mg.
Cardio-vascular system: hypotension, angina pectoris.
Hemopoietic system: thrombocytopenia.
CNS: vertigo, dizziness, headache, asthenia syndrome (fatigue, lethargy, malaise).
Respiratory system: bronchitis, pharyngitis, rhinitis, cough.
Digestive system: diarrhea, dyspepsia, gastroenteritis, abdominal pain, nausea, vomiting, increased liver enzymes.
Dermatological reactions: itching, rash, angioedema, atopic dermatitis, facial edema, urticaria.
Musculoskeletal system: arthritis, back pain, bone pain, muscle cramps, myalgia, increased activity of CK.Urinary system: hematuria, urinary tract infection.
Metabolism: hypertriglyceridemia, hyperuricemia, hyperkalemia, increased serum creatinine and urea in serum, peripheral edema.
Other: chest pain, flu-like symptoms.
Obstruction of the biliary tract, pregnancy, lactation, childhood and adolescence under the age of 18 years.
Olmetor is contraindicated for use during pregnancy and lactation.
Due to the lack of sufficient clinical experience does not recommended the use of Olmetor in patients with severe renal insufficiency (creatinine clearance < 20 mL / min), patients with impaired liver function.
Olmetor used with caution in patients with stenosis of the aortic or mitral valves or obstructive hypertrophic cardiomyopathy.
In the case of previous intensive therapy with diuretics, human salt-free diet, diarrhea and / or vomiting after the first dose may been developed hypotension as a result of reducing the BCC. Thats why it is necessary to eliminate the possibility of hypovolemia before starting treatment with Olmetor.
Olmetor should be used with caution for patients with heart failure, kidney disease, renal artery stenosis in both or only one kidney because of the risk of acute hypotension, azotemia, oliguria, acute renal failure.
When treating patients with impaired renal function it is recommended periodic monitoring of potassium and creatinine in serum.
It is not recommended of Olmetor using in patients with primary hyperaldosteronism.
It should be borne in mind that excessive lowering of blood pressure in patients with coronary artery disease or atherosclerosis of cerebral vessels may lead to the development of myocardial infarction or ischemic stroke.
While taking of Olmetor occasionally there may be dizziness or fatigue which should be considered in the application of patients, control of vehicles and / or engaged in other potentially hazardous activities.
Simultaneous administration of Olmetor with:
Symptoms: pronounced reduction in blood pressure, tachycardia.
Treatment: when pronounced reduction of blood pressure is recommended to lay the patient on his back and lifted his legs. There is recommended a gastric lavage and / or reception of activated charcoal therapy aimed at correcting dehydration and violations of water-salt metabolism, supplementation of BCC.
Depending on the reaction of the Olmetor after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Olmetor not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.
Is Olmetor addictive or habit forming?Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.
Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.
There are no reviews yet. Be the first to write one! |
The information was verified by Dr. Rachana Salvi, MD Pharmacology